CN101304743B - 刺激神经形成和抑制神经元变性的方法和组合物 - Google Patents

刺激神经形成和抑制神经元变性的方法和组合物 Download PDF

Info

Publication number
CN101304743B
CN101304743B CN2006800414246A CN200680041424A CN101304743B CN 101304743 B CN101304743 B CN 101304743B CN 2006800414246 A CN2006800414246 A CN 2006800414246A CN 200680041424 A CN200680041424 A CN 200680041424A CN 101304743 B CN101304743 B CN 101304743B
Authority
CN
China
Prior art keywords
compounds
compound
compositions
pharmaceutical composition
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2006800414246A
Other languages
English (en)
Chinese (zh)
Other versions
CN101304743A (zh
Inventor
J·凯莱赫·安迪生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuronascent Inc
Original Assignee
Neuronascent Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuronascent Inc filed Critical Neuronascent Inc
Priority to CN201210246309.XA priority Critical patent/CN102743382B/zh
Priority to CN201610900496.7A priority patent/CN106474118A/zh
Publication of CN101304743A publication Critical patent/CN101304743A/zh
Application granted granted Critical
Publication of CN101304743B publication Critical patent/CN101304743B/zh
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2006800414246A 2005-09-19 2006-09-19 刺激神经形成和抑制神经元变性的方法和组合物 Active CN101304743B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201210246309.XA CN102743382B (zh) 2005-09-19 2006-09-19 刺激神经形成和抑制神经元变性的方法和组合物
CN201610900496.7A CN106474118A (zh) 2005-09-19 2006-09-19 刺激神经形成和抑制神经元变性的方法和组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US71869105P 2005-09-19 2005-09-19
US60/718,691 2005-09-19
US82220206P 2006-08-11 2006-08-11
US60/822,202 2006-08-11
PCT/US2006/036463 WO2007035722A2 (en) 2005-09-19 2006-09-19 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201210246309.XA Division CN102743382B (zh) 2005-09-19 2006-09-19 刺激神经形成和抑制神经元变性的方法和组合物
CN201610900496.7A Division CN106474118A (zh) 2005-09-19 2006-09-19 刺激神经形成和抑制神经元变性的方法和组合物

Publications (2)

Publication Number Publication Date
CN101304743A CN101304743A (zh) 2008-11-12
CN101304743B true CN101304743B (zh) 2012-09-05

Family

ID=37889462

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2006800414246A Active CN101304743B (zh) 2005-09-19 2006-09-19 刺激神经形成和抑制神经元变性的方法和组合物
CN201610900496.7A Pending CN106474118A (zh) 2005-09-19 2006-09-19 刺激神经形成和抑制神经元变性的方法和组合物
CN201210246309.XA Active CN102743382B (zh) 2005-09-19 2006-09-19 刺激神经形成和抑制神经元变性的方法和组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201610900496.7A Pending CN106474118A (zh) 2005-09-19 2006-09-19 刺激神经形成和抑制神经元变性的方法和组合物
CN201210246309.XA Active CN102743382B (zh) 2005-09-19 2006-09-19 刺激神经形成和抑制神经元变性的方法和组合物

Country Status (12)

Country Link
US (3) US8039462B2 (OSRAM)
EP (1) EP1937252B1 (OSRAM)
JP (1) JP5554496B2 (OSRAM)
KR (2) KR101158568B1 (OSRAM)
CN (3) CN101304743B (OSRAM)
AU (1) AU2006292256B2 (OSRAM)
CA (2) CA2800945C (OSRAM)
DK (1) DK1937252T3 (OSRAM)
IL (3) IL190179A (OSRAM)
PL (1) PL1937252T3 (OSRAM)
RU (1) RU2440346C2 (OSRAM)
WO (1) WO2007035722A2 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039462B2 (en) * 2005-09-19 2011-10-18 Neuronascent, Inc. Methods and compositons for stimulating neurogenesis and inhibiting neuronal degeneration
JP5781077B2 (ja) * 2009-09-22 2015-09-16 ニューロナセント インコーポレイテッド ダウン症を治療するための方法および薬学的組成物
CA2754237A1 (en) * 2011-05-27 2012-11-27 The Regents Of The University Of California Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof
KR102074530B1 (ko) * 2012-03-06 2020-02-06 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 조합 요법에 의한 프로카스파제 ３ 활성화
WO2015036412A1 (en) * 2013-09-12 2015-03-19 F. Hoffmann-La Roche Ag Indol-carboxamide derivatives
RU2630654C2 (ru) * 2015-07-29 2017-09-11 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Балтийский Федеральный Университет имени Иммануила Канта" (БФУ им. И. Канта) Способ хемогенетической регистрации и коррекции нейрогенеза на основе генетических конструкций для трансфекции астроцитов и нейронов
RU2670128C2 (ru) * 2016-12-16 2018-10-18 Федеральное государственное автономное образовательное учреждение высшего образования "Балтийский федеральный университет имени Иммануила Канта" (БФУ им. И. Канта) Способ генетической регистрации и коррекции нейрогенеза на основе генетических конструкций для трансфекции нейронов
KR20190081385A (ko) 2017-12-29 2019-07-09 강원대학교산학협력단 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
KR20190081386A (ko) 2017-12-29 2019-07-09 강원대학교산학협력단 루핀아마이드를 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
EP4352058A4 (en) * 2021-06-11 2025-09-24 Neuronascent Inc METHODS AND COMPOSITIONS FOR LIPID FORMULATION OF SMALL MOLECULE THERAPIES WITH LIPOPHILIC HETEROCYCLIC TYPES

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3571489A (en) * 1966-12-23 1971-03-16 Max Levy & Co Inc Transparent substrate having graded optical density conductors thereon
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3612745A (en) * 1970-07-08 1971-10-12 Sierracin Corp Flexural bus bar assembly
US4057671A (en) * 1975-06-27 1977-11-08 Ppg Industries, Inc. Heated laminated window and method of assembling same
US4089809A (en) * 1976-03-01 1978-05-16 The United States Of America As Represented By The United States Department Of Energy Regenerable sorbent and method for removing hydrogen sulfide from hot gaseous mixtures
US4233871A (en) * 1978-04-26 1980-11-18 Alessi Anthony A Notching tool
EP0032578B1 (de) * 1980-01-16 1984-07-25 Hans Georg Prof. Dr. Weder Verfahren und Dialysiereinrichtung zur Herstellung von Bilayer-Vesikeln und Verwendung der Bilayer-Vesikel
US4361751A (en) * 1980-07-24 1982-11-30 Ppg Industries, Inc. Electroconductive window having improved bus bar
US4323726A (en) * 1980-07-24 1982-04-06 Ppg Industries, Inc. Electrical bus bar assembly
GR79603B (OSRAM) * 1982-07-24 1984-10-31 Pfizer
US4485054A (en) * 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4438253A (en) * 1982-11-12 1984-03-20 American Cyanamid Company Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same
US4540786A (en) * 1983-08-22 1985-09-10 The Dow Chemical Company Preparation of 2-chloro-3-cyano-quinolines
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4532089A (en) * 1984-01-14 1985-07-30 Northwestern University Method of preparing giant size liposomes
US4897269A (en) * 1984-09-24 1990-01-30 Mezei Associates Limited Administration of drugs with multiphase liposomal delivery system
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
GB9425986D0 (en) * 1994-12-22 1995-02-22 Pilkington Glass Ltd Electrically heated window
US5820880A (en) * 1995-06-07 1998-10-13 The United States Of America As Represented By The Secretary Of The Army Liposomal formulation
US5665428A (en) * 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
RU2221785C2 (ru) * 1998-09-22 2004-01-20 Яманоути Фармасьютикал Ко., Лтд. Гетероциклическое производное, фармацевтическая композиция, его содержащая, и промежуточный продукт
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
US6287588B1 (en) * 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
JP2003523940A (ja) * 1999-05-11 2003-08-12 オーソ−マクネイル ファーマシューティカル インコーポレイテッド エリスロポエチン投与の薬物速度論的および薬力学的モデリング
EP1309567A2 (en) * 2000-08-18 2003-05-14 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic compounds
US6974818B2 (en) * 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
AU2003247772A1 (en) * 2002-06-27 2004-01-19 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
AU2004221812B2 (en) * 2003-03-19 2010-02-18 Exelixis Inc. Tie-2 modulators and methods of use
EP1631992A2 (en) * 2003-06-12 2006-03-08 Patterning Technologies Limited Transparent conducting structures and methods of production thereof
US8039462B2 (en) * 2005-09-19 2011-10-18 Neuronascent, Inc. Methods and compositons for stimulating neurogenesis and inhibiting neuronal degeneration

Also Published As

Publication number Publication date
KR20110084556A (ko) 2011-07-25
WO2007035722A3 (en) 2007-07-19
EP1937252A2 (en) 2008-07-02
IL230807B (en) 2018-01-31
CA2800945C (en) 2017-12-05
US20150209371A1 (en) 2015-07-30
AU2006292256A1 (en) 2007-03-29
DK1937252T3 (da) 2017-11-20
IL190179A (en) 2014-02-27
IL190179A0 (en) 2008-11-03
RU2008109821A (ru) 2009-10-27
US20080234253A1 (en) 2008-09-25
US8999972B2 (en) 2015-04-07
CN101304743A (zh) 2008-11-12
EP1937252A4 (en) 2010-07-28
CA2800945A1 (en) 2007-03-29
CN102743382B (zh) 2016-12-07
RU2440346C2 (ru) 2012-01-20
KR20080065616A (ko) 2008-07-14
WO2007035722A8 (en) 2007-11-29
CA2623507A1 (en) 2007-03-29
KR101158568B1 (ko) 2012-07-02
CN102743382A (zh) 2012-10-24
CN106474118A (zh) 2017-03-08
EP1937252B1 (en) 2017-10-25
US20110319391A1 (en) 2011-12-29
WO2007035722A2 (en) 2007-03-29
JP2009508876A (ja) 2009-03-05
PL1937252T3 (pl) 2018-01-31
AU2006292256B2 (en) 2013-05-02
CA2623507C (en) 2013-03-12
KR101132378B1 (ko) 2012-04-03
IL230807A0 (en) 2014-03-31
WO2007035722B1 (en) 2008-02-07
JP5554496B2 (ja) 2014-07-23
IL256489A (en) 2018-02-28
US9539261B2 (en) 2017-01-10
US8039462B2 (en) 2011-10-18

Similar Documents

Publication Publication Date Title
US8999972B2 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
AU2008265600B2 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
CA3220429A1 (en) Methods and compositions for lipid formulation of lipophilic small molecule therapies of the heterocyclic type
AU2013245563B2 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
AU2013211455A1 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant